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Parkinson’s disease (PD) is the second most common form of neurodegeneration in the elderly population. Clinically, it is
characterized by tremor, rigidity, slowness of movement, and postural imbalance. A signiﬁcant association between low serum
vitamin D and PD has been demonstrated, suggesting that elevated vitamin D levels might provide protection against PD. Genetic
studies have helped identify a number of proteins linking vitamin D to PD pathology, including the major histocompatibility
complex(MHC)classII,thevitaminDreceptor(VDR),cytochromeP4502D6(CYP2D6),chromosome22,therenin-angiotensin
system (RAS), heme oxygenase-1 (HO-1), poly(ADP-ribose) polymerase-1 gene (PARP-1), neurotrophic factor (NTF), and Sp1
transcription factor. Vitamin D has also been implicated in PD through its eﬀects on L-type voltage-sensitive calcium channels
(L-VSCC), nerve growth factor (NGF), matrix metalloproteinases (MMPs), prostaglandins (PGs) and cyclooxygenase-2 (COX-
2), reactive oxygen species (ROS), and nitric oxide synthase (NOS). A growing body of evidence suggests that vitamin D
supplementation may be beneﬁcial for PD patients. Among the diﬀerent forms of vitamin D, calcitriol (1,25-dihydroxyvitamin
D3) is best indicated for PD, because it is a highly active vitamin D3 metabolite with an appropriate receptor in the central nervous
system (CNS).
1.Introduction
Parkinson’s disease (PD) is a movement disorder char-
acterized by tremor, rigidity, slowness of movement, and
postural imbalance. There is evidence of abnormalities in
the vitamin D-endocrine system in PD patients, including
low bone mineral density (BMD), decreased vitamin D
levels, and increased bone turnover makers (bone alkaline
phosphatase and urinary N-terminal telopeptide of type I
collagen) compared to controls [1]. These factors, combined
with balance problems, are the probable reasons for the
high incidence of fractures, especially of the hip, reported in
elderly women with PD [2]. Sunlight exposure can increase
the BMD of PD by increasing serum 25-hydroxyvitamin
D3 (25OHD) levels [3]. In another study, serum 25OHD
and BMD were reported to be reduced in PD patients. The
BMD Z-score of the trochanter was directly correlated to
the degree of physical activity and total body BMD Z-score
correlated to the degree of rigidity [4]. Osteoporosis and
osteopenia are common ﬁndings in PD patients, aﬀecting up
to 91% of women and 61% of men [5]. Decreased BMD, low
concentrations of serum ionized calcium, and compensatory
hyperparathyroidism increase the risk of hip fracture in PD
patients [1]. Despite an abundance of correlational studies,
it is unknown whether vitamin D deﬁciency is a cause or
consequence of PD. In the present paper, we review the
hypothesized roles of vitamin D in PD pathogenesis.
2.GenomicFactorsAssociatedwith
VitaminDinParkinson’s Disease
2.1. Major Histocompatibility Complex (MHC). Studies have
suggested that several genes in the MHC region promote
susceptibility to PD. Signiﬁcantly increased levels of MHC
class II expressions were detected in the cerebrospinal ﬂuid
(CSF) monocytes of PD patients [6]. Human leukocyte
antigen (HLA) genes have also been implicated in PD, and
large numbers of HLA-DR-positive reactive microglia were
detected in the substantia nigra (SN) and the nigrostriatal
tract in PD patients [7, 8]. HLA-DR-positive microglia have
also been found in these regions in a case of Parkinson’s-
associated dementia in Guam [8]. Conversely, calcitriol2 ISRN Neurology
(1,25-dihydroxyvitamin D3) is known to stimulate phagocy-
tosis but suppress MHC class II antigen expression in human
mononuclear phagocytes [9, 10]. Calcitriol also decreases
interferon-gamma-induced HLA-DR antigen expression on
normal and transformed human keratinocytes [11, 12].
TheseﬁndingssuggestedthatvitaminDmaymodulateMHC
class II antigen expression in PD.
2.2. Vitamin D Receptor (VDR). There is ample evidence
for vitamin D involvement in mammalian brain function.
VDR and 1α-hydroxylase, the enzyme responsible for the
formation of active vitamin D in the human brain, are
found in the large neurons of the SN, as well as in neurons
and glial cells in the hypothalamus [13]. VDR, a nuclear
r e c e p t o r ,i sr e s t r i c t e dt ot h en u c l e u sb u t1 α-hydroxylase is
distributed throughout the cytoplasm. The presence of these
proteins in the CNS suggests that vitamin D is active within
the brain. VDR knockout mice have muscular and motor
impairment [14]. Genetic studies provide an opportunity
to link molecular variations with epidemiological data,
DNA sequence variations, such as polymorphisms, exert
subtle biological eﬀects on the expression and functionality
of proteins. VDR mRNA was identiﬁed as a potential
blood marker for PD [15]. In a Korean population, the
VDR BsmI genotype is reported to be associated with
PD [16]. Butler et al. [17] reported that the VDR gene
is a potential susceptibility gene for PD in the Caucasian
population. These reports suggested a role of vitamin D in
PD.
2.3. The Cytochrome P450 (CYP). CYP superfamily of
enzymes is responsible for the oxidation, peroxidation,
and/or reduction of vitamins, steroids, and xenobiotics, as
well as the metabolism of drugs. CYP2D6, an important
member of this superfamily, is expressed in neurons in
the brain and gut and may be inﬂuenced by polymorphic
expression. There is a higher prevalence of the poor-
metabolizingCYP2D6∗4alleleinPDpatientscomparedwith
controls (20.7% versus 11.0%) [18]. In case-control and
meta-analysis studies, the CYP2D polymorphism was found
tobeassociatedwithPD[19,20].Otherstudies,however,did
not ﬁnd an association between the CYP2D6 polymorphism
and PD in an Asian population [21, 22]. Although the
poor metabolizer genotype has a small but highly signiﬁcant
association with PD, it would be easily missed in studies with
modestnumbersofsubjects.CYP2D6proteinandenzymatic
activityarecompletelyabsentinlessthan1%ofAsianpeople
and in up to 10% of Caucasians with two null alleles [23].
Singhetal.reportedtheexpressionofCYP2D22,anortholog
of human CYP2D6, in mouse striatum and its modulation
in MPTP-induced PD phenotype and nicotine-mediated
neuroprotection [24]. CYP2D6 is a potential 25-hydroxylase,
which converts vitamin D3 into 25OHD, and vitamin D
25-hydroxylase deﬁciency resulted in vitamin D deﬁciency
[25]. Moreover, the CYP2D and PD loci are located on the
same chromosome 22 [26, 27]. Deletion of chromosome
22q11 syndrome was reported to be associated with PD [28,
29]. Interestingly, patients with a deletion of chromosome
22q11 showed a reduced BMD, serum calcium, and PTH
levels; 11% and 8% of these patients had serum 25OHD
levels under 20ng/ml and abnormal serum 1,25OHD levels,
respectively [30].
2.4.TheRenin-AngiotensinSystem(RAS). Theprimaryfunc-
tion of the RAS is to maintain ﬂuid homeostasis and regulate
bloodpressure.SeveralcomponentsoftheRASanditsrecep-
tors are found in the CNS [31–34], suggesting that RAS is
important in the brain. CSF levels of angiotensin-converting
enzyme (ACE) activity were reported to be decreased in PD
patientsandincreasedwithdopaminergictreatment[35,36].
Inaddition,theACEinhibitorperindoprilhasbeenshownto
exert beneﬁcial eﬀects on the dopaminergic system [37, 38].
After four weeks of treatment with perindopril, patients
with PD had faster improvement in motor response after L-
dopa and a reduction in “on phase” peak dyskinesia [39].
The frequency of the homozygous DD genotype of the ACE
gene was signiﬁcantly increased in patients with PD, and is
also higher in PD patients with L-dopa-induced psychosis
versuswithoutpsychosis[40,41].However,otherstudiesdid
not reveal any associations between ACE polymorphisms,
PD, and of L-dopa-induced adverse eﬀects [42, 43]. The
dissimilarﬁndingsmaybeattributabletodiﬀerencesbetween
Chinese and Caucasian populations. Interestingly, there is
also an interaction between vitamin D and the RAS. The use
of ACE inhibitors by the ACE DD genotype has been shown
to decrease the level of calcitriol [44]. In addition, genetic
disruption of the VDR resulted in overstimulation of the
RAS with increased production of renin and angiotensin II,
thereby leading to high blood pressure and cardiac hypertro-
phy. Treatment with captopril reduced cardiac hypertrophy
in VDR knockout mice [45], suggesting that calcitriol may
function as an endocrine suppressor of renin biosynthesis.
Vitamin D has also been reported to decrease ACE activity
in bovine endothelial cells [46]. The ﬁndings suggested that
vitamin D might aﬀect ACE activity in PD.
2.5. Heme Oxygenase-1 (HO-1). HO-1 is a stress protein
that may confer cytoprotection by enhancing catabolism of
pro-oxidant heme to the radical scavenging bile pigments,
biliverdin, and bilirubin. The HO-1 gene can be upregulated
by a host of noxious stimuli and is induced in CNS
tissues aﬀected by neurological diseases [47]. In the normal
brain, basal HO-1 expression is low and restricted to small
groups of scattered neurons and neuroglia [48]. In the
brains of PD patients, the HO-1 is highly overexpressed
in astrocytes within the SN and in Lewy bodies found in
aﬀected dopaminergic neurons [49]. Serum HO-1 levels are
increased in PD patients but not in patients with Alzheimer’s
disease (AD) [50], suggesting a systemic antioxidant reaction
to a chronic oxidative stress state that is unique to PD.
Similarly, calcitriol delayed of HO-1 immunoreactivity after
thepostlesionalsurvivaltimeof12hoursconcomitantwitha
reduction in glial ﬁbrillary acidic protein immunoreactivity
in remote cortical regions aﬀected by a secondary spread of
injuryinglialcellsofthefocalcerebralischemic[51],thereby
supporting the protective role of calcitriol in postcellular
injury.ISRN Neurology 3
2.6. Poly(ADP-Ribose) Polymerase-1 (PARP-1). PARP-1 is a
nuclear protein that can promote either neuronal death or
survival under certain stress conditions. Overexpression of
PARP-1 has been reported in the dopaminergic neurons of
the SN in PD [52]. PARP-1 is also implicated in 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine- (MPTP-) induced neu-
rotoxicity in vivo [53]. MPTP is a neurotoxin that induces
parkinsonian symptoms in human and animals, but mice
lacking PARP gene are spared from MPTP neurotoxicity
[54]. Therefore, PARP inhibitors have proved to be valuable
tools in PD model [55, 56]. PARP-1 variants are reported
t ob ep r o t e c t i v ea g a i n s tP D[ 57]. In addition, increased
levelsofvitaminDseemtodownregulatePARP-1expression;
PARP-1 levels decrease following calcitriol treatment in
NB4 cells, which represent an acute promyelocytic leukemia
cells [58]. Vitamin D exerts a concentration-dependent
inhibitory eﬀect on PARP-1 in the human keratinocyte
cells [59]. Vitamin D-induced downregulation of PARP is
further enhanced by nicotinamide in human myeloblastic
leukemia cells [60]. Furthermore, PARP is attenuated in
the hippocampus of rats that received dexamethasone and
vitaminD[61],suggestingthattheanti-inﬂammatoryeﬀects
ofdexamethasoneandvitaminDderivesfromtheirabilityto
downregulatemicroglialactivation.Theseﬁndingssuggested
that vitamin D may have a protective role in PD by
downregulating PARP.
2.7. Neurotrophic Factors (NTFs). NTFsarekeystosurviving
various neuronal insults and promote neuronal regener-
ation following injury [62]. NTFs can exert protective
or even restorative eﬀects on PD animal models and
dopaminergic cell cultures; key examples include brain-
derived neurotrophic factor (BDNF) [63], glial-derived
neurotrophic factor (GDNF) [64], mesencephalic-astrocyte-
derived neurotrophic factor (MANF) [65], and cerebral
dopamine neurotropic factor (CDNF) [66]. Receptors for
these NTFs are expressed in the striatum and SN [67, 68].
NTF expression is reduced in the SN of patients with PD
[69–71]. Moreover, the C allele of an inotropic CDNF single
nucleotide polymorphism (rs7094179) has been suggested
to infer susceptibility to PD in a Korean population [72],
and A allele of BDNF is associated with PD in a Chinese
Han population [73]. Interestingly, calcitriol regulates the
expression of the low-aﬃnity neurotrophic receptor [74]
and increases striatal GDNF mRNA and protein expression
in adult rats [75]. In vivo,c a l c i t r i o li sa l s oap o t e n t
inducer of GDNF in rat glioma cells [76]. The brains of
oﬀspring from vitamin D-deﬁcient dams are characterized
by diminished expression of neurotrophic factors [77].
Furthermore, calcitriol protects against dopamine loss from
6-hydroxydopamine- (6-OHDA-) lesioned rats by increasing
GDNF and partially restores tyrosine hydroxylase expression
in SN and striatum [78, 79].
2.8. Sp1 Transcription Factor. Sp1 transcription factor is a
member of an extended family of DNA-binding proteins
that is acetylated in response to oxidative stress in neurons
[80]. The Sp1 family of proteins plays an important role
in controlling the expression of the dopamine transporter
gene within dopaminergic neurons [81] and also regulates
expression of rat dopamine receptor gene [82]. On the other
hand, binding sites for the transcription factor Sp1 have
been implicated in the transcription of several genes by
hormones. In cultured human ﬁbroblasts, the level of CYP24
(25-OHD 24-hydroxylase) mRNA plays a key role in the
metabolism of 1,25OHD and increases up to 20,000-fold in
response to calcitriol. Two vitamin D-responsive elements
(VDREs) located upstream of the CYP24 gene are primarily
responsible for the increased mRNA levels, and Sp1 acted
synergistically with these VDREs for the induction [72]. The
mVDRpromoteriscontrolledbySp1sites[73]andfunctions
as the transactivation component of the VDR/Sp1 complex
totriggergeneexpression[74].Moreover,thegenesencoding
Sp1 and VDR were mapped to human chromosome 12q
[75, 76].
3. Nongenomic Role of VitaminD in
Parkinson’sDisease
3.1. Diabetes Mellitus (DM). Glucose is the molecule nec-
essary to produce energy in the brain. A link between
DM and PD has been suggested in several reports, but the
results have been inconsistent. Insulin receptors and their
mRNAs are localized in the SN [83, 84]. A high incidence
of abnormal glucose tolerance has been reported in PD and
seems to be exacerbated by L-dopa treatment [85]. DM has
been associated with the risk of developing PD [86, 87]
whereas others reported from protective to no associations
with PD [88–90]. Human and experimental animal studies,
however, demonstrated neurodegeneration associated with
peripheral insulin resistance [91]. In a 6-OHDA model of
PD, striatal insulin resistance was observed in the striatum
[92], and patients with PD exhibited increased autoimmune
reactivity to insulin [93]. Individuals newly diagnosed with
PD display reduced insulin-mediated glucose uptake [94],
which is hypothesized to be due to inhibit early insulin
secretion and hyperglycemia after glucose loading [95].
Furthermore, chronic hyperglycemia decreased limbic extra-
cellular dopamine concentrations and striatal dopaminergic
transmission in streptozotocin-induced diabetic rats [96,
97]. Vitamin D levels may provide a link between the
diseases; serum 1,25OHD and 25OHD levels are low in
diabetic patients [98, 99], and diabetic rats had an increased
metabolic clearance rate of 1,25OHD [100]. Interestingly,
a signiﬁcant high prevalence of vitamin D insuﬃciency
is reported in patients with PD [101, 102]. A signiﬁcant
inverse association between serum vitamin D and PD was
demonstrated[103]andsuggestedthathighvitaminDstatus
might provide protection against PD. In diabetic-induced
rats, vitamin D and insulin treatment markedly recovered
the levels of altered gene (cholinergic, dopaminergic, and
insulin receptors) expression and its binding parameters
nearly to those of the control rats [104]. Maternal vitamin
D deﬁciency was reported to alter the expression of genes
involved in dopamine speciﬁcation in the developing rat
mesencephalon [105]. Calcitriol has been shown to pro-
tect dopamine neuronal toxicity induced by 6-OHDA and
the combination of L-buthionine sulfoximine and MPTP,4 ISRN Neurology
thereby restoring motor activity in the lesioned animals
[106, 107]. Furthermore, vitamin D was reported to improve
rigidity and akinesia and reduce levodopa dosage in a patient
with PD [108].
3.2. L-Type Voltage-Sensitive Calcium Channels (L-VSCC).
Unlike most neurons in the brain, dopaminergic neurons
function as autonomous pacemakers that rely on L-VSCC
to generate action potentials at a clock-like 2–4Hz in
the absence of synaptic input [109]. L-VSCC activity dur-
ing autonomous pacemaking increased the sensitivity of
dopaminergic neurons to mitochondrial toxins in an animal
model of PD [110]. Epidemiological data supports a link
between L-VSCC functioning and the risk of developing
PD [111–113]. Pretreatment with the calcium channel
antagonist nimodipine has been shown to block the devel-
opment of MPTP-induced neurotoxicity in animal models
[114, 115]. Israpidine, another L-VSCC antagonist, caused
a dose-dependent reduction in L-dopa-induced rotational
behavior and abnormal involuntary movements in the 6-
OHDA-lesioned rat model of PD [116]. With respect to AD,
amyloid-β protein was reported to promote neurodegenera-
tion by inducing L-VSCC expression and suppressing VDR
expression; subsequent treatment with vitamin D protected
neurons by preventing cytotoxicity and apoptosis, probably
by downregulating L-VSCC and upregulating VDR [117].
Calcitriol decreased L-VSCC activity in aged rats and in
neuronal vulnerability with particular impact on reducing
age-related changes associated with Ca2+ dysregulation [118,
119]. Treatment with 24R, 25 dihydroxyvitamin D3 also
reduced L-VSCC activity in vascular smooth muscle in rats
[120].
3.3. Nerve Growth Factor (NGF). NGF is a small secreted
protein that is important for the growth, maintenance, and
survival of certain target neurons. NGF has been impli-
cated in maintaining and regulating the septohippocampal
pathway, which is involved in learning and memory [121–
123]. NGF is also present in the human SN [124] and in
the adrenal gland [125]. NGF concentrations are decreased
in the SN of the PD and in a rat model of PD [69, 126].
NGF levels showed greater reductions in early states of
the disease compared with advanced stages [126], implying
that decreased NGF may be involved in the pathogenesis
of PD. NGF is reported to protect dopamine neurotoxicity
induced by MPTP, rotenone, and 6-OHDA via diﬀerent
pathways [127–129]. The chronic infusion of NGF into
the rat striatum resulted in cholinergic hyperinnervation
and reduced spontaneous activity of striatal neurons [130].
Moreover, NGF increases survival of dopaminergic grafts,
rescues nigral dopaminergic neurons, and restores motor
dysfunction in a rat model of PD [131, 132]. In addition,
the brains of newborn rats from vitamin D-deﬁcient dams
showed reduced expression of NGF [77]. In vitro,c a l c i t r i o l
regulated the expression of the VDR gene and stimulated the
expressionoftheNGFgeneinSchwanncells[133].Inmouse
ﬁbroblasts, calcitriol and vitamin D analogs are reported to
enhance NGF induction by increasing AP-1 binding activity
to the NGF promoter [134, 135]. These ﬁndings suggest a
protective role for vitamin D in the CNS.
3.4. Matrix Metalloproteinases (MMPs). MMPs are prote-
olytic enzymes responsible for extracellular matrix (ECM)
remodeling and the regulation of leukocyte migration
through the ECM, which is an important step for inﬂamma-
tory processes. Neuroinﬂammation is known to contribute
signiﬁcantly to progressive dopaminergic neurodegenera-
tion in PD. MMP involvement has been reported in the
degeneration of dopaminergic neurons. MMP-3 expression
is increased during lipopolysaccharide- (LPS-) induced
dopamine neurotoxicity [136]. MMP-9 is also elevated in
MPTP-induced parkinsonism in mice [137]. Application of
dopaminergic neurotoxins to two human neuroblastoma
cell lines downregulates the transcription and translation of
tissue inhibitor of metalloproteinase- (TIMP-) 2 eﬀectively
enhancing MMP activity [138]. Exendin-4, which is an
analogue of glucagon-like peptide 1 (GLP-1), signiﬁcantly
attenuates the loss of SN neurons and the striatal dopamin-
ergic ﬁbers in the MPTP-induced PD model, and inhibits
the expression of MMP-3 [139]. Conversely, the VDR TaqI
polymorphism is associated with decreased production of
TIMP-1, a natural inhibitor of MMP-9 [140]. Calcitriol
modulates tissue MMP expression under experimental con-
ditions [141]. Calcitriol downregulates MMP-9 levels in
keratinocytes and may attenuate deleterious eﬀects due to
excessive TNF-α-induced proteolytic activity associated with
cutaneous inﬂammation [142]. In addition, a vitamin D
analogue was reported to reduce the expression of MMP-2,
MMP-9, VEGF, and parathyroid hormone-related protein in
Lewis lung carcinoma cells [143]. These ﬁndings suggested
that vitamin D plays a role in modulating MMP activation in
PD.
3.5. Prostaglandins (PGs). PGs play a role in inﬂammatory
processes [144]. Cyclooxygenase (COX) participates in the
conversion of arachidonic acid into PGs. PGE2 is a key
product of COX-2 and is increased in the SN of patients with
PD and MPTP-induced PD in an animal model [145, 146].
PGE2 is also directly and selectively toxic to dopaminergic
neurons [147]. PGE2 receptors are found on dopaminergic
neurons in the rat SN [147]. Overexpression of COX-2 is
reported in PD and an MPTP-animal model [148, 149].
COX inhibitors provide neuroprotection in the MPTP-
mouse model of PD [150]. Similarly, regular use of COX-2
inhibiting nonsteroidal anti-inﬂammatory drugs (NSAIDs),
such as ibuprofen, has been associated with a decreased
incidence of PD [151]. Calcitriol, which reportedly regulates
the expression of several key genes involved in PG pathways,
decreases PG synthesis [152]. Calcitriol and its analogues
have also been shown to inhibit selectively the activity of
COX-2 [153]. These ﬁndings suggested that vitamin D has
a role in anti-inﬂammatory processes in PD.
3.6. Oxidative Stress. Oxidative stress has been suggested to
contribute to the pathogenesis of PD. Lymphocytes from
untreated PD patients have increase oxidative stress [154].
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of increased lipid peroxidation in PD SN [155, 156]. A
selective superoxide dismutase (SOD) is also increased in
the SN of PD patients [157]. Calcitriol administration has
been reported to exert a receptor-mediated eﬀect on the
secretion of hydrogen peroxide by human monocytes [158].
In vitro, monocytes gradually lose their ability to produce
superoxide when stimulated; the addition of calcitriol,
lipopolysaccharide, or lipoteichoic acid (LTA) restored the
ability of stimulated monocytes to produce superoxide and
increases the oxidative capacity compared with unstimulated
monocytes [159]. Calcitriol can also protect nonmalignant
prostate cells from oxidative stress-induced cell death by
preventing ROS-induced cellular injuries [160]. Vitamin
D metabolites and analogues were reported to induce
lipoxygenase mRNA expression, lipoxygenase activity, and
ROS production in a human bone cell line [161]. Vitamin D
can also reduce lipid peroxidation and induce SOD activity
in the rat hepatic antioxidant system [162]. These ﬁndings
suggested a role of vitamin D in oxidative stress in PD.
3.7. Nitric Oxide Synthase (NOS). NOS is an enzyme
involved in the synthesis of nitric oxide (NO), which has
also been implicated in PD. In postmortem brains of PD,
high levels of NOS expression were found in the nigrostriatal
region and basal ganglia [163]. A signiﬁcant increase in
the nitrite content was reported in polymorphonuclear
leukocytes of PD patients [164]. Inducible and neuronal NO
are increased in both 6-OHDA and MPTP animal models
[165, 166]. Moreover, studies with NOS inhibitors and NOS
knock-out animals have also conﬁrmed the role of NOS in
neurodegeneration [167, 168]. Reduced and oxidized glu-
tathione(GSH)weredemonstratedintheSNofpatientswith
PD [169]. Conversely, the activation of 1α-hydroxylase in
macrophagesincreasesin1,25OHD,whichinhibitsinducible
NOS (iNOS) expression and reduces NO production by
lipopolysaccharide- (LPS-) stimulated macrophages [170].
Thus, calcitriol production by macrophages may provide
protection against oxidative injuries caused by the NO
burst. Calcitriol is known to inhibit LPS-induced immune
activation in human endothelial cells [171]. In experimental
allergic encephalomyelitis, calcitriol inhibits the expression
of iNOS in the rat CNS [172]. Astrocytes play a pivotal role
in CNS detoxiﬁcation pathways where glutathione (GSH) is
involved in the elimination of oxygen and nitrogen reactive
species, such as nitric oxide. Calcitriol aﬀects this pathway by
enhancing intracellular GSH pools and signiﬁcantly reduces
nitrite production induced by LPS [173].
4. Conclusion
Recent studies have highlighted a possible relationship
between vitamin D and PD. Vitamin D may be beneﬁcial
in PD patients, as one patient showed improved rigidity
and akinesia and was able to decrease their levodopa dosage
after vitamin D therapy. Genetic studies have provided
opportunities to determine what proteins may link vitamin
D to PD pathology. Vitamin D can also act through
a number of nongenomic mechanisms, including eﬀects
on protein expression, oxidative stress, inﬂammation, and
cellular metabolism. Among the many forms of vitamin
D, calcitriol (1,25-dihydroxyvitamin D3) is an attractive
therapeutic candidate, because it is a particularly active
metabolite, and its receptor is expressed in the CNS.
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